A New Era in the Diagnosis and Treatment of Genitourinary Syndrome of Menopause

Today, I had the honor of delivering an educational lecture at the 7th GSM Research Meeting.

One of the most important highlights of this meeting was the recent publication of a joint guideline on Genitourinary Syndrome of Menopause (GSM) by the American Urological Association (AUA) and three collaborating academic societies. This represents a major milestone in the field.

GSM is an extremely common condition affecting postmenopausal women worldwide. However, despite its high prevalence, it has long remained underrecognized and undertreated. Many patients have suffered from symptoms that were often considered vague, nonspecific, or simply an inevitable part of aging.

The publication of this guideline marks a significant shift. GSM is no longer regarded as a collection of ambiguous symptoms. It is now clearly recognized as a definable, diagnosable, and treatable medical condition. This recognition represents a major step forward for clinical practice and for patients.

GSM and Recurrent Cystitis: Understanding the True Underlying Mechanism

Recurrent cystitis is one of the most common and distressing problems in postmenopausal women.

Traditionally, management has focused on:

Repeated courses of antibiotics Lifestyle modifications Increased fluid intake

However, GSM fundamentally alters the biological environment through:

Loss of mucosal integrity Decreased local defense mechanisms Alteration of the vaginal microbiome

In other words, these patients are not simply “getting repeated infections.”

They are in a state where the body can no longer effectively prevent infection.

This distinction is critical.

Local estrogen therapy and other GSM-targeted treatments often result in dramatic improvement in patients with recurrent cystitis. This highlights the importance of treating the underlying tissue and restoring the biological environment, rather than relying solely on antibiotics.

Emerging therapies, including vaginal laser treatment, have also shown promising results in improving vaginal tissue health and reducing recurrent cystitis episodes.

This represents a paradigm shift—from treating infection alone to restoring physiological defense mechanisms.

GSM Treatment Is Expanding—But It Is Not the Whole Story

Awareness of GSM is rapidly increasing, and treatment options have expanded to include:

Local estrogen therapy Vaginal laser therapy Other regenerative approaches

However, some patients continue to experience persistent symptoms despite appropriate GSM treatment.

In many of these cases, the underlying issue lies in the pelvic floor.

The Pelvic Floor: The Invisible but Critical Factor

The pelvic floor muscles play essential roles in:

Urination Defecation Sexual function Pelvic organ support

When pelvic floor dysfunction occurs—such as:

Muscle overactivity Poor coordination Myofascial pelvic pain syndrome (MPPS)

Patients may develop symptoms remarkably similar to GSM, including:

Urinary frequency Bladder discomfort Recurrent cystitis-like symptoms Pelvic pain Dyspareunia

These patients are often misdiagnosed or inadequately treated if pelvic floor dysfunction is not recognized.

The pelvic floor is frequently an “invisible cause.”

A Shared Understanding Among Experts

One of the most encouraging aspects of this research meeting was the deep understanding among participating physicians regarding the role of pelvic floor dysfunction.

Concepts such as MPPS were readily understood and integrated into clinical thinking.

This reflects a growing global shift toward a more comprehensive, integrative understanding of pelvic floor disorders.

When We Can Diagnose, We Can Treat

The establishment of GSM guidelines and the growing recognition of pelvic floor dysfunction represent a turning point.

Conditions that were once labeled as:

“Unknown cause” “Untreatable” “Something patients must live with”

are now increasingly recognized as:

Treatable medical conditions.

Diagnosis changes everything.

Bringing Light to Conditions That Have Remained in the Shadows

Many patients have long suffered without answers.

We now understand that the underlying causes are often:

Genitourinary Syndrome of Menopause (GSM) Pelvic floor dysfunction

When we can identify the true cause, we can provide effective treatment.

Our mission is to visualize what has been invisible, to uncover hidden causes, and to ensure that no patient becomes a medical refugee.

We will continue advancing both clinical care and research to improve the lives of patients affected by pelvic floor disorders.

Bringing light to conditions that have remained in the shadows.